Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de terapia neural cardíaca para insuficiencia cardíaca (NECTAR-HF) (NECTAR-HF)

26 de octubre de 2026 actualizado por: Boston Scientific Corporation

Estudio de terapia neural cardíaca para la insuficiencia cardíaca

The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve stimulation in heart failure patients with a New York Heart Association Class III, an ejection fraction equal to or less than 35 %, and a narrow QRS duration equal to or less than 130 ms.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

The objectives of this study are to assess the impact of right vagal nerve stimulation on left ventricular remodeling, functional capacity, quality of life, and other measures in heart failure patients over a 6-month period. In addition, the study will assess the safety of the NECTAR-HF study system over an 18-month period.

Tipo de estudio

Intervencionista

Inscripción (Actual)

118

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Göttingen, Alemania, 37075
        • Universitätsmedizin Göttingen
      • Hamburg, Alemania, 20246
        • Universitäres Herzzentrum GmbH, Universitätsklinikum Hamburg-Eppendorf
      • Leipzig, Alemania, 04103
        • Universitätsklinikum Leipzig
    • Brandenburg
      • Bernau bei Berlin, Brandenburg, Alemania, 16321
        • Immanuel Klinikum Bernau Herzzentrum Brandenburg
      • Brussels, Bélgica, 1200
        • UCL Bruxelles
      • Prague, Chequia, 15030
        • Nemocnice Na Homolce
      • Barcelona, España, 08036
        • Hospital Clinic de Barcelona
      • Madrid, España, 28041
        • Hospital Doce de Octubre
    • Navarre
      • Pamplona, Navarre, España, 31008
        • Clínica Universitaria de Navarra, Avenida Pio XII s/n
      • Lille, Francia, 59037
        • CHRU de Lille - Hôpital Cardiologique
    • Nancy
      • Vandœuvre-lès-Nancy, Nancy, Francia, 54500
        • Centre d'Investigation Clinique Pierre Drouin, CHU de Nancy
      • Milan, Italia, 20162
        • Azienda Ospedaliera Niguarda Cà Granda
      • Naples, Italia, 80131
        • A. O. Dei Colli - Monaldi
      • Pavia, Italia, 27100
        • Policlinico San Matteo
      • Eindhoven, Países Bajos, 5623EJ
        • Catharina Ziekenhuis Eindhoven
      • Utrecht, Países Bajos, 3584CX
        • UMC Utrecht
      • London, Reino Unido, SE5 9RS
        • King's College Hospital NHS Foundation Trust
    • England
      • Bristol, England, Reino Unido, BS2 8HW
        • University Hospitals Bristol, NHS Foundation Trust
      • Liverpool, England, Reino Unido, L14 3PD
        • Liverpool Heart and Chest Hospital, NHS Foundation Trust
      • London, England, Reino Unido, W1G 8PH
        • The Heart Hospital, University College London Hospitals, NHS Foundation Trust
      • London, England, Reino Unido, W2 1NY
        • Imperial College Healthcare NHS Trust, St. Mary's Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age 18 or above, and of legal age to give informed consent specific to national laws
  • Willing and capable of providing informed consent
  • Capable of participating in all testing associated with this clinical investigation
  • Stable symptomatic heart failure NYHA class II-III
  • Left ventricular (LV) ejection fraction equal or smaller than 35 %
  • Left ventricular end diastolic diameter (LVEDD) of 5.5 cm or greater
  • Prescribed to optimal pharmacologic therapy

Exclusion Criteria:

  • QRS larger than 130 ms
  • Patients who have been hospitalized for heart failure and who required the use of HF IV therapy within 30 days before enrollment
  • Patients unable to tolerate anesthesia required for implant
  • Patients with unstable angina, myocardial infarction, PTCA, coronary artery bypass graft, cerebral vascular accident, or transient ischemic attack within previous 90 days before enrollment
  • Patients whose primary cause of heart failure is mitral or aortic valve disease, with a severe classification
  • Patients with persistent or permanent atrial fibrillation within 90 days prior to enrollment
  • Pacemaker indicated patients
  • Patients whose heart failure is due to congenital heart disease
  • Patients who have started treatment for sleep apnea or sleep disordered breathing with therapies to maintain airway patency (e.g., CPAP, Bi-PAP,APAP) with or without oxygen supplementation within the previous 6 months prior to enrollment
  • Patients with hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g. amyloidosis, sarcoidosis)
  • Patients with documented chronic obstructive lung disease
  • Patients on or indicated for renal dialysis
  • Type 1 diabetic patients
  • Type 2 diabetic patients that have been treated with insulin for more than 5 years prior to enrollment
  • Patients with a life expectancy of less than 12 months per physician judgment
  • Patients involved in any concurrent clinical investigation
  • Women of childbearing potential who are or might be pregnant at the time of the study or breastfeeding
  • Patients with a prior cardiac transplant or expecting a heart transplant operation within the next 12 months
  • Patients with a prior vagotomy
  • Patients with prior or existing vagal nerve stimulation treatment
  • Patients implanted with any active implantable medical device other than a left sided single or dual chamber implantable cardioverter defibrillator (ICD) with bipolar sensing, or a left sided CRT device with each sensing channel programmed to either bipolar sensing or no sensing. All CRT patients must have had CRT for at least 1 year prior to enrollment. The total number of CRT patients will not exceed 30
  • Patients with locally implanted semi-/permanent devices such as vascular catheters, etc. that would interfere with the NECTAR-HF study system
  • Patients with previously implanted devices on the right side that became infected before removal
  • Patients with previous neck surgery and resultant scar formation that interferes with the ability to implant the study system on the right side of the neck (Thyroid/parathyroid, carotid artery etc)
  • Patients with known recurrent nerve paralysis
  • Patients who have undergone radiotherapy for thyroid disease/cancer
  • Patients who have existing or prior tracheotomy
  • Patients with severe vertebral cervical disease and limited mobility in the neck; includes those that frequently wear a brace
  • Patients with carotid murmur/vascular bruit/carotid artery lesion
  • Patients with known/suspected vascular malformation in carotid/vertebral circulatory bed
  • Patients who are likely to need an MRI of the neck area because of previous medical conditions

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Therapy

Implant of investigational device system for vagus nerve stimulation. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period.

The experimental arm was receiving vagus nerve stimulation during the first 6 months after implant.

Titration during the randomization phase with delivery of highest tolerable by patient stimulation current.

Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current.

Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.

Amplitude of the chronically delivered vagus nerve stimulation in the experimental arm was adjusted to the highest tolerable by patient value. No chronically delivered vagus nerve stimulation in the control arm during the randomization phase.

Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.

Blood draw before implant and 6 months after implant at the end of the randomization phase.

Comparador falso: Control

Implant of investigational device system for vagus nerve stimulation. Control group was implanted with study system like the experimental arm, but was not receiving experimental vagus nerve stimulation therapy during the first 6 months after implant. 6-month after implant a cross-over took place and the control arm also started to receive experimental vagus nerve stimulation.

Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current.

Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.

Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.

Blood draw before implant and 6 months after implant at the end of the randomization phase.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Left Ventricular End-systolic Dimension (LVESD)
Periodo de tiempo: LVESD at Baseline and at 6-months post Baseline

Change in the Left ventricular end-systolic dimension (LVESD) between Baseline and the value at the end of the randomization phase (6 months after Baseline) i.e. 6 months after vagus nerve stimulation in the THERAPY Arm. No Vagus nerve stimulation during that time window in the CONTROL Arm.

The sign (- ) indicates a reduction in the LVESD. Minus means a reduction in LVESD.

The change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 6 months minus value at baseline).

LVESD at Baseline and at 6-months post Baseline
Percentage of Surviving Participants
Periodo de tiempo: 18-months

As pre-specified in the study protocol, the All-cause Survival endpoint combined both groups into one analysis population. Subjects contributed data according to the follow-up period during they received VNS therapy (Implant through 18 months for Therapy subjects, 6 through 18 months for Control subjects). Control patients who exited the study in the first 6 months, or who did not have a 6 month visit, were excluded.

18-months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
LVEF, Left Ventricular Ejection Fraction
Periodo de tiempo: LVEF at Baseline and at 6-months after Baseline

LVEF, left ventricular ejection fraction.

LVEF at Baseline and at 6-months after Baseline
Exercise Capacity, Peak VO2
Periodo de tiempo: Measurements at Baseline and at 6-months after Baseline

Assessment of functional capacity (e.g., peak VO2) as measures related to patient heart failure status.

Measurements at Baseline and at 6-months after Baseline
LVESV, Left Ventricular End Systolic Volume
Periodo de tiempo: At Baseline and at 6-months after Baseline

Measurements of LVESV, left ventricular end systolic volume at Baseline and 6 months after Baseline in the Control Arm and in the Therapy Arm

At Baseline and at 6-months after Baseline

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Faiez Zannad, M.D., Centre d'Investigation Clinique (CIC), Batiment Louis Mathieu, CHU de Nancy

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

21 de septiembre de 2011

Finalización primaria (Actual)

1 de mayo de 2014

Finalización del estudio (Estimado)

30 de junio de 2027

Fechas de registro del estudio

Enviado por primera vez

28 de junio de 2011

Primero enviado que cumplió con los criterios de control de calidad

28 de junio de 2011

Publicado por primera vez (Estimado)

30 de junio de 2011

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

28 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

26 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • NECTAR-1109

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .